https://www.avient.com/sites/default/files/resources/PolyOne%25202017%2520Annual%2520Report.pdf
While we view our patents and trademarks to be valuable because of the broad scope
of our products and services and brand recognition we enjoy, we do not believe that the loss or expiration of any
single patent or trademark would have a material adverse effect on our results of operations, financial position or
cash flows.
The accruals represent our
best estimate of probable future costs that we can reasonably estimate, based upon currently available information
and technology and our view of the most likely remedy.
https://www.avient.com/sites/default/files/resources/PolyOne%25202013%2520Annual%2520Report.pdf
While we view our patents and
trademarks to be valuable because of the broad scope of our products and services and brand
recognition we enjoy, we do not believe that the loss or expiration of any single patent or trademark
would have a material adverse effect on our results of operations, financial position or cash flows.
The
accruals represent our best estimate of probable future costs that we can reasonably estimate, based
upon information and technology that is currently available and our view of the most likely remedy.
https://www.avient.com/sites/default/files/resources/PolyOne%25202014%2520Annual%2520Report.pdf
While we view our patents and
6 POLYONE CORPORATION
trademarks to be valuable because of the broad scope of our products and services and brand
recognition we enjoy, we do not believe that the loss or expiration of any single patent or trademark
would have a material adverse effect on our results of operations, financial position or cash flows.
The
accruals represent our best estimate of probable future costs that we can reasonably estimate, based
upon information and technology that is currently available and our view of the most likely remedy.
https://www.avient.com/sitemap
PolyOne Launches NEU™ View Technology for Radiopaque Translucent Catheters